Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP-1050 vs Xulane Skin Irritation and Sensitization Study
NCT04624867Phase 1Unknown
- Sponsor
- Noven Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of HP-1050 in contraception, sponsored by Noven Pharmaceuticals. Primary endpoints: Skin Irritation Evaluation at 21 days and Sensitization Evaluation at 48 hours. Status: unknown.
02
Drugs
HP-1050
03
Conditions
contraception
Beyond the preview
Go deeper on NCT04624867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624867.